Direct attack on the second batch of volume purchase bidding site, Bayer acarbose decreased by more than 90%

[industry trends of pharmaceutical network] on January 17, the second batch of volume purchase was officially opened in Shanghai 122 enterprises began to offer prices around 33 varieties of drugs, and the proposed bid winning results will be generated on that day According to the second batch of on-site media reports, on the morning of the 17th, in the process of quoting for several hours, simvastatin won the bid by Jingxin Pharmaceutical Co., Ltd., abitlong oral drug was awarded the bid by Hengrui Pharmaceutical Co., Ltd., and adefovir dipivoxil oral drug was awarded the bid by guangshengtang Among foreign enterprises, Bayer won the bid for acarbose oral regular release agent, and bringer Ingelheim won the bid for meloxicam oral regular release agent Among them, acarbose, a hypoglycemic drug from Bayer, the original research and development enterprise, was quoted as a shocking low price by the transferor, which triggered a call on the spot It is understood that in the second batch of bidding for carrying capacity procurement, acarbose's bidding enterprises include Huadong Pharmaceutical Co., Ltd., Zhongmei Huadong Pharmaceutical Co., Ltd., LVYE Pharmaceutical Co., Ltd and Bayer Co., Ltd., three subsidiaries of Huadong Pharmaceutical Co., Ltd., with prices of 13.96 yuan, 9.6 yuan and 5.42 yuan respectively, and specifications of 50mg / 30 tablets Bayer's quotation is 5.42 yuan / box, with a decrease of more than 90% The single-chip price is 0.1807 yuan, which is nearly 80% lower than 0.8353 According to the public information, the median price of Acarbose Tablets of Bayer was 2.14 yuan / tablet for 50mg and 3.53 yuan / tablet for 100mg In this round of bidding, Huadong pharmaceutical unfortunately failed to win the bid, and acarbose, the main variety of Huadong pharmaceutical, once occupied the second largest market share, accounting for 30% Data shows that in 2018, the sales of acarbose in East China medicine reached 2.535 billion yuan According to the calculation of 30% market share, the domestic market sales in 2019 was about 8.45 billion yuan It can be seen that if the outgoing news is true, it really has a great impact on the company According to the industry, acarbose is a very concerned variety among the 33 varieties purchased in the second batch As a long-term antidiabetic drug for diabetes patients, its market is very broad The data shows that the prevalence of hypertension, dyslipidemia and diabetes is 25.2%, 40.4% and 9.7% respectively in Chinese residents aged 18 and over According to the new statistics, there are more than one diabetes patient in every 10 adults in China, and the current patient population is about 114 million Among all the hypoglycemic drugs, acarbose has become one of the most widely used oral antidiabetic drugs in China because of its outstanding advantages in controlling postprandial blood sugar and its suitability for Chinese diet It is reported that in 2018, the market value of acarbose products in China is estimated to be about 10 billion yuan According to the sales data of chemical oral hypoglycemic drugs in China's sample hospitals in 2018, the total market share of acarbose and metformin in chemical oral hypoglycemic drugs exceeds 50% Among them, acarbose accounted for 33% and metformin 18% However, the author noted that metformin did not enter the second round of the catalogue Industry said that from the current outflow of the second round of varieties decline, the overall decline of this round of centralized purchase is expected to be larger than the previous round It is expected that drug prices will continue to decline in the future In addition, recently, the industry also reported that more than 160 varieties before the purchase amount of the hospital, especially more than three varieties that have passed the consistency evaluation will be included in the collection In general, with the further deepening and normalization of centralized mining in the future, pharmaceutical enterprises need to take a long-term view, lay out the fields of innovative drugs and APIs in advance, and do a good job of integration, transformation and upgrading, so as to seize the market opportunity.